Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magnus Pedersen

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
British Journal of Cancer|March 21, 2019
Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancerMarie Christine Wulff Westergaard, Rikke Andersen, Chloé Chong, et al.
Oncotarget|June 18, 2020
Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancerAnders Handrup Kverneland, Magnus Pedersen, Marie Christine Wulff Westergaard, et al.
Journal for Immunotherapy of Cancer|July 2, 2021
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanomaTroels Holz Borch, Katja Harbst, Aynal Haque Rana, et al.
Oncoimmunology|December 8, 2018
Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot studyMagnus Pedersen, Marie Christine Wulff Westergaard, Katy Milne, et al.
Cancers|December 23, 2020
Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian CancerMarie Christine Wulff Westergaard, Katy Milne, Magnus Pedersen, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
British Journal of Cancer|March 21, 2019
Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancerMarie Christine Wulff Westergaard, Rikke Andersen, Chloé Chong, et al.
Oncotarget|June 18, 2020
Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancerAnders Handrup Kverneland, Magnus Pedersen, Marie Christine Wulff Westergaard, et al.
Journal for Immunotherapy of Cancer|July 2, 2021
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanomaTroels Holz Borch, Katja Harbst, Aynal Haque Rana, et al.
Oncoimmunology|December 8, 2018
Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot studyMagnus Pedersen, Marie Christine Wulff Westergaard, Katy Milne, et al.
Cancers|December 23, 2020
Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian CancerMarie Christine Wulff Westergaard, Katy Milne, Magnus Pedersen, et al.
Pageof 2